spec sheet6 rows
Bifeprunox was Solvay Pharmaceuticals' and Wyeth's answer to aripiprazole: a partial dopamine D2 receptor agonist paired with 5-HT1A partial agonism, designed to stabilize dopamine tone (dialing it down where too high, propping it up where too low) rather than blunt it uniformly the way older antipsychotics do. Solvay and Wyeth filed for FDA approval in October 2006 with data spanning acute schizophrenia treatment and long-term relapse prevention. The FDA's August 2007 decision acknowledged some efficacy but rejected the application, judging the evidence insufficient to show meaningful advantages over already-approved drugs, and flagging safety questions along the way. The companies pursued a bit more data afterward, but by July 2009 all development activities were halted for good, ending bifeprunox's run as the almost-aripiprazole of American psychiatry.
- some efficacy against positive and negative symptoms acknowledged by the FDA review
- partial-agonist mechanism intended to reduce extrapyramidal and prolactin side effects versus full D2 antagonists
- long-term relapse-prevention data also submitted alongside acute-treatment data
- safety concerns contributed to the 2007 unapprovable decision
- Bifeprunox got as far as an FDA filing in 2006, well past where most drugs in this archive ever reach, before regulators turned it down in 2007.
Mechanism
Partial at receptors combined with partial agonism at receptors, the same combined mechanism class as aripiprazole.
Safetyrisks and cautions, not medical advice
One participant died during the trial programme, and the FDA's 2007 refusal letter asked the sponsors specifically to explain that case, reported as multi-organ failure, along with questions about how the drug is metabolised in people. The refusal itself was mostly about efficacy: the agency accepted that bifeprunox beat placebo in two short-term studies but found the evidence insufficient against antipsychotics already on the market, with safety questions compounding it. Development stopped entirely in 2009, so no long-term human safety database was ever assembled and now none will be.
History
Developed by Solvay Pharmaceuticals with Wyeth as US marketing partner; FDA application filed October 2006, rejected (deemed unapprovable) in August 2007 for insufficient efficacy evidence and safety concerns; all development halted in July 2009.
Subjective profileweighing the evidence above
A mechanistically sound aripiprazole-adjacent drug that simply couldn't clear the FDA's efficacy bar against an already-crowded field of approved atypicals.
Resources
This entry is here for reference.
Research
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
Why is bifeprunox compared to aripiprazole?
Both drugs share the same core mechanism, partial agonism at dopamine D2 receptors combined with 5-HT1A partial agonism, but aripiprazole (Abilify) made it to market and bifeprunox did not.
Did bifeprunox fail because it didn't work at all?
Not exactly. The FDA acknowledged it had some efficacy but ruled the data didn't clearly show an advantage over drugs already on the market, and safety concerns compounded the rejection.
Limitations of the evidence
- FDA found the efficacy evidence insufficient relative to already-approved antipsychotics
- development ultimately halted entirely by 2009
Adverse effects
- safety concerns contributed to the 2007 unapprovable decision